---
title: "TIBET PHARMA released its 2024 annual performance, with a net profit attributable to the parent company of 1.051 billion yuan, a year-on-year increase of 31.26%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/231824726.md"
description: "TIBET PHARMA released its 2024 annual report, with revenue of 2.807 billion yuan, a year-on-year decrease of 10.45%; net profit attributable to shareholders of 1.051 billion yuan, a year-on-year increase of 31.26%; net profit excluding non-recurring items of 859 million yuan, a year-on-year increase of 9.45%; basic earnings per share of 3.26 yuan. The company plans to distribute a cash dividend of 7.28 yuan for every 10 shares to shareholders. The decline in revenue is mainly due to a decrease in sales of new active ingredients, leading to a drop in sales revenue. During the reporting period, the company received industrial support funds of 213.7486 million yuan"
datetime: "2025-03-14T09:04:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/231824726.md)
  - [en](https://longbridge.com/en/news/231824726.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/231824726.md)
---

# TIBET PHARMA released its 2024 annual performance, with a net profit attributable to the parent company of 1.051 billion yuan, a year-on-year increase of 31.26%

According to the Zhitong Finance APP, Tibet Pharma (600211.SH) disclosed its 2024 annual report. During the reporting period, the company achieved revenue of 2.807 billion yuan, a year-on-year decrease of 10.45%; net profit attributable to shareholders was 1.051 billion yuan, a year-on-year increase of 31.26%; net profit excluding non-recurring gains and losses was 859 million yuan, a year-on-year increase of 9.45%; basic earnings per share were 3.26 yuan. The company plans to distribute a cash dividend of 7.28 yuan (including tax) for every 10 shares to all shareholders.

The decline in revenue was mainly due to a decrease in the sales volume of new active ingredients this year, which affected sales revenue.

During the reporting period, the following matters had a significant impact on the company's net profit: 1. In the ongoing adjustment of the pharmaceutical industry, the company's product sales revenue contracted to some extent, with main business revenue for 2024 at 2,799.9863 million yuan, a year-on-year decrease of 10.49%. Sales of new active ingredients accounted for 86.89% of annual sales revenue, a decrease of 13.62% compared to the same period last year; other products had sales revenue of 367.0916 million yuan, a year-on-year increase of 17.81%. 2. The company received industrial support funds of 213.7486 million yuan during this period

### Related Stocks

- [600211.CN](https://longbridge.com/en/quote/600211.CN.md)

## Related News & Research

- [Tourist arrivals up 10% year on year in April, driven by Hong Kong Sevens](https://longbridge.com/en/news/286512798.md)
- [07:56 ETWellen Park marks 10 years among America's top-selling master-planned communities](https://longbridge.com/en/news/286766568.md)
- [10:30 ETInventHelp Inventor Develops New Line of Candies (SGM-681)](https://longbridge.com/en/news/286931125.md)
- [10:45 ETInventHelp Inventor Develops New Illuminated Display (SGM-649)](https://longbridge.com/en/news/286933598.md)
- [China Upgrades Departure Tax Refund Policy for Foreign Visitors](https://longbridge.com/en/news/286868862.md)